Daiwa Cuts Target Price for GENSCRIPT BIO (01548) to HK$21, Reiterates "Buy" Rating

Stock News

Mar 18

Daiwa released a research report indicating that GENSCRIPT BIO (01548) delivered results in line with expectations last year. Sales increased by 61% year-on-year to $960 million, matching the firm's forecast of $961 million. Adjusted net profit rose by 285% to $230 million. The firm maintained its "Buy" rating on GENSCRIPT BIO but lowered the target price from HK$26 to HK$21, reflecting a lower valuation for its associate company Legend Biotech (LEGN.US). Regarding guidance for the current year, GENSCRIPT BIO anticipates revenue for its Genscript Life Science (LSG) segment to grow by 15% to 18% year-on-year, with an adjusted gross margin of approximately 52% and an adjusted operating profit margin of around 19%. The company also forecasts its ProBio segment revenue to increase by 20% to 25%, achieving positive EBITDA by 2027. Additionally, Daiwa reduced its earnings per share forecasts for the company for 2026 and 2027 by 10% and 1%, respectively.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers | Global Stocks, Options & Futures Trading App","description":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","keywords":"tiger brokers,tiger trade,tiger brokers singapore,broker online,stock trading in singapore,share trading singapore,brokerage firm singapore,trading app,stock broker singapore,stock trading platforms,trading account","social":{"ogDescription":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www-web.itiger.com/news/1113306341"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"isCrawlerRequest":true,"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"1113306341\",edition:\"fundamental\",auth_exemption:1,,,undefined,":{"share":"https://ttm.financial/m/news/1113306341?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2026-03-18 14:28","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"1113306341","market":"us","top_or_hot":-1,"title":"Daiwa Cuts Target Price for GENSCRIPT BIO (01548) to HK$21, Reiterates \"Buy\" Rating","media":"Stock News","content":"<p>Daiwa released a research report indicating that GENSCRIPT BIO (01548) delivered results in line with expectations last year. Sales increased by 61% year-on-year to $960 million, matching the firm's forecast of $961 million. Adjusted net profit rose by 285% to $230 million. The firm maintained its \"Buy\" rating on GENSCRIPT BIO but lowered the target price from HK$26 to HK$21, reflecting a lower valuation for its associate company Legend Biotech (LEGN.US). Regarding guidance for the current year, GENSCRIPT BIO anticipates revenue for its Genscript Life Science (LSG) segment to grow by 15% to 18% year-on-year, with an adjusted gross margin of approximately 52% and an adjusted operating profit margin of around 19%. The company also forecasts its ProBio segment revenue to increase by 20% to 25%, achieving positive EBITDA by 2027. Additionally, Daiwa reduced its earnings per share forecasts for the company for 2026 and 2027 by 10% and 1%, respectively.</p>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Daiwa Cuts Target Price for GENSCRIPT BIO (01548) to HK$21, Reiterates \"Buy\" Rating</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nDaiwa Cuts Target Price for GENSCRIPT BIO (01548) to HK$21, Reiterates \"Buy\" Rating\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1036600163\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/b3bf6d02ad1a6e9e7377eebbb162346a);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Stock News </p>\n<p class=\"h-time\">2026-03-18 14:28</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<p>Daiwa released a research report indicating that GENSCRIPT BIO (01548) delivered results in line with expectations last year. Sales increased by 61% year-on-year to $960 million, matching the firm's forecast of $961 million. Adjusted net profit rose by 285% to $230 million. The firm maintained its \"Buy\" rating on GENSCRIPT BIO but lowered the target price from HK$26 to HK$21, reflecting a lower valuation for its associate company Legend Biotech (LEGN.US). Regarding guidance for the current year, GENSCRIPT BIO anticipates revenue for its Genscript Life Science (LSG) segment to grow by 15% to 18% year-on-year, with an adjusted gross margin of approximately 52% and an adjusted operating profit margin of around 19%. The company also forecasts its ProBio segment revenue to increase by 20% to 25%, achieving positive EBITDA by 2027. Additionally, Daiwa reduced its earnings per share forecasts for the company for 2026 and 2027 by 10% and 1%, respectively.</p>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"HK0000320264.USD","symbol_name":"TAIKANG KAITAI CHINA NEW OPPORTUNITIES FUND \"A\" (USD) ACC","start_time":0,"source_url":"","article_id":"1113306341","we_media_id":"1036600163","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=1113306341","pubTimestamp":1773815299,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Stock News","introduction":"Global Stock News First-Time Broadcast","home_visible":1,"id":"1036600163","head_image":"https://community-static.tradeup.com/news/b3bf6d02ad1a6e9e7377eebbb162346a"},"summary":"Daiwa released a research report indicating that GENSCRIPT BIO (01548) delivered results in line with expectations last year. Sales increased by 61% year-on-year to $960 million, matching the firm's...","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"HK0000320264.USD":"TAIKANG KAITAI CHINA NEW OPPORTUNITIES FUND \"A\" (USD) ACC","01548":"金斯瑞生物科技","HK0000320223.HKD":"TAIKANG KAITAI CHINA NEW OPPORTUNITIES FUND \"A\" (HKD) ACC","HK0000306685.HKD":"TAIKANG KAITAI CHINA NEW OPPORTUNITIES FUND \"A\" (HKD) INC","BK1583":"高瓴概念","BK1141":"生命科学工具和服务","BK1576":"医药外包概念","HK0000306701.USD":"TAIKANG KAITAI CHINA NEW OPPORTUNITIES FUND \"A\" (USD) INC"},"translate_title":"大和下调金斯瑞生物(01548)目标价至21港元重申“买入”评级","themeId":"","isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"01548":1},"content_text":"Daiwa released a research report indicating that GENSCRIPT BIO (01548) delivered results in line with expectations last year. Sales increased by 61% year-on-year to $960 million, matching the firm's forecast of $961 million. Adjusted net profit rose by 285% to $230 million. The firm maintained its \"Buy\" rating on GENSCRIPT BIO but lowered the target price from HK$26 to HK$21, reflecting a lower valuation for its associate company Legend Biotech (LEGN.US). Regarding guidance for the current year, GENSCRIPT BIO anticipates revenue for its Genscript Life Science (LSG) segment to grow by 15% to 18% year-on-year, with an adjusted gross margin of approximately 52% and an adjusted operating profit margin of around 19%. The company also forecasts its ProBio segment revenue to increase by 20% to 25%, achieving positive EBITDA by 2027. Additionally, Daiwa reduced its earnings per share forecasts for the company for 2026 and 2027 by 10% and 1%, respectively.","kind":"news","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"","news_rank":0,"symbols":[],"gpt_button":0,"need_auth":false,"code":"91000000","status":"200"}}}